Skip to main content

Abivax S.A. (AAVXF)

New York Stock Exchange Healthcare BiotechnologyView data quality →
35.4Poor

ValueMarkers Composite Index

Top 2%#43,836 of 44,707
Overvalued

1287% above intrinsic value ($10)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-
Altman
40.44
Safe
DCF Value
$10
Overvalued
ROIC
-48.0%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Abivax S.A. (AAVXF) — VMCI valuation read

AAVXF screens at VMCI 35/100, a 15-point gap below the Healthcare sector median (50). For a mid-cap Abivax S.A. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

AAVXF has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: AAVXF trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 3.5x is the binding constraint on the bear case, which sets the rate-cycle exposure for Abivax S.A..

AAVXF rose 3.8% over the trailing 7 days, with a -12.3% read on a 30-day basis.

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

CEO: Marc de Garidel69 employeesFRwww.abivax.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in AAVXF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.